Download PDF
CC BY-NC-ND 4.0 · Asian J Neurosurg 2012; 7(04): 181-190
DOI: 10.4103/1793-5482.106650
ORIGINAL ARTICLE

Five-year follow-up results for patients diagnosed with anaplastic astrocytoma and effectiveness of concomitant therapy with temozolomide for recurrent anaplastic astrocytoma

Feyzi Sarica
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
,
Melih Cekinmez
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
,
Kadir Tufan
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
,
Orhan Sen
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
,
Huseyin Onal
1   Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara
,
Huseyin Mertsoylu
2   Department of Medical Oncology, Baskent University Faculty of Medicine, Ankara
,
Erkan Topkan
1   Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara
,
Berrin Pehlivan
1   Department of Radiation Oncology, Baskent University Faculty of Medicine, Ankara
,
Bulent Erdogan
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
,
Mehmet Altinors
Department of Neurosurgery, Baskent University Faculty of Medicine, Ankara
› Author Affiliations
› Further Information
  PDF Download Permissions and Reprints

Background: Anaplastic astrocytoma (AA; WHO grade-III) patients determination of prognostic factors helps generating multimodal therapy protocols. For this purpose, in the Baskent University, Adana Medical Research Center, specific characteristics of AA patients who have surgery were retrospectively investigated and factors which affect prognosis has been determined. Patients and Methods: Between January 2005 and 2009, 20 patients who have AA have been evaluated retrospectively. Totally, 20 patients had 31 operations. Sixteen patients had only adjuvant radiation therapy (RT). In the postoperative period, 8 patients received adjuvant RT. Nine of 10 patients with tumor recurrence received concomitant therapy with temozolomide (ConcT with TMZ) protocol. No adjuvant therapy protocol could be applied in three patients with poor general condition in the postoperative period. Results: Median survival for patients died was 16±17 months; one year survival was 75% and five year survival 25%. After univariate analysis, preoperative Karnofsky performance score (KPS) was ≥80 ( P=0.005577FNx01), postoperative KPS was ≥80 ( P=0.003825FNx01), type of tumor resection ( P=0.001751FNx01), multiple operations ( P=0.006233FNx01), and ConcT with TMZ protocol ( P=0,005766FNx01) were all positive prognostic factors which extend the survival. Conclusions: The results of the multivariate analysis did not put forward an independent prognostic factor acting on the survival period ( P>0.05).

Key-words:

Anaplastic astrocytoma - concomitant therapy - prognostic factor - recurrence - temozolomide


Publication History

Article published online:
27 September 2022

© 2012. Asian Congress of Neurological Surgeons. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India